Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment

Future Medicinal Chemistry Editorial by Daniel Merk (Goethe University Frankfurt, Germany) discussing the potential of retinoid X receptor gamma-targeting agents to repair or reverse multiple sclerosis damage to the CNS through boosting remyelination.

Although a significant focus of the regenerative medicine field lies in cell therapy and stem cells, the application of pharmacological science has the potential to promote the repair or regeneration of tissues and organs both in vivo and in vitro.

Multiple sclerosis is an area of significant unmet medical need, with ~2.1 million individuals affected across the globe, and no existing therapies that can reverse or repair the autoimmune destruction of the CNS. In a Future Medicinal Chemistry Editorial, Daniel Merk (Goethe University Frankfurt, Germany) discusses the potential of retinoid X receptor gamma-targeting agents to repair or reverse multiple sclerosis damage to the CNS through boosting remyelination, while noting some challenges such as small-molecule delivery to the CNS.

Merk D. Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment. Future Med. Chem. 7(18), 2411—2413 (2015).